Compare Medpace Holdings Inc (MEDP) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs MINISO Group Holding Ltd — how do they compare? Medpace Holdings Inc trades at $530.31 (market cap $15.08B), while MINISO Group Holding Ltd trades at $12.52 (market cap $3.87B). The key difference: Medpace Holdings Inc is far larger — about 3.9× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.21% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MNSO | |
|---|---|---|
Market Cap | $15.08B | $3.87B |
Sector | Technology | Technology |
52-Week High | $620.59 | $26.63 |
52-Week Low | $308.88 | $11.30 |
Enterprise Value | $14.55B | $4.54B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal driven by moving averages. The stock shows strong fundamentals with a P/E of 12.98 and net income margin of 8.98% for 2026. Recent Q1 2026 earnings beat expectations with EPS of $0.591, and the company announced a HK$2 billion share repurchase program on June 29, 2026, signaling confidence.
Outlook is positive given earnings momentum and valuation support, but risks include margin pressure from overseas expansion costs and mixed quarterly performance. Analyst consensus is 75% buy, though one sell rating highlights growth execution concerns. The stock remains a growth play with manageable valuation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
